Pheochromocytoma and paraganglioma

What is Pheochromocytoma and paraganglioma?

Pheochromocytoma and paraganglioma (PPGL) are rare neuroendocrine tumors that develop from chromaffin cells and secrete excess catecholamines like adrenaline and noradrenaline. Pheochromocytomas arise in the adrenal glands, while paragangliomas occur in nerve tissue outside the adrenal glands, particularly along the spine and in the head and neck region. These tumors affect approximately 0.8 per 100,000 people annually and can occur at any age, though they most commonly appear in adults between 40-50 years old. While most cases are benign, the excessive hormone production can cause life-threatening cardiovascular complications if left untreated.

Key statistics

Symptoms

Classic triad: episodic hypertension, severe headaches, profuse sweating, heart palpitations

The hallmark symptoms result from excessive catecholamine release and typically occur in episodes lasting minutes to hours. Patients experience sudden onset of severe headaches described as throbbing or pounding, often accompanied by profuse sweating that soaks clothing. Heart palpitations may feel like the heart is racing or skipping beats, while blood pressure can spike dangerously high during episodes.

Additional symptoms include: chest or abdominal pain, nausea and vomiting, anxiety or panic attacks, tremors, pale skin during episodes, weight loss despite normal appetite, and fatigue between episodes. Some patients develop sustained high blood pressure rather than episodic symptoms. Paragangliomas in the head and neck may cause hearing problems, difficulty swallowing, or voice changes. Episodes can be triggered by physical activity, certain foods, medications, or stress.

Submit Your Paper

Causes and risk factors

Approximately 40% of PPGLs are hereditary, caused by mutations in genes including RET, VHL, SDHB, SDHC, SDHD, SDHAF2, and NF1. These genetic syndromes often cause multiple tumors and may be associated with other conditions. The remaining 60% are sporadic cases with unknown triggers, though some may have unidentified genetic causes.

Risk factors include: family history of PPGL or related genetic syndromes, personal history of other neuroendocrine tumors, and certain genetic conditions like von Hippel-Lindau disease, neurofibromatosis type 1, or multiple endocrine neoplasia type 2. The hereditary forms typically present at younger ages and have higher rates of bilateral adrenal involvement or multiple tumors.

Prevention

There is no known prevention for sporadic PPGLs. For hereditary cases, genetic counseling and testing are crucial for at-risk family members. Carriers of pathogenic mutations require lifelong surveillance with regular biochemical testing and imaging to detect tumors early. Genetic testing should be considered for all PPGL patients, as identifying a hereditary syndrome allows for appropriate screening of family members and personalized surveillance protocols. Preconception genetic counseling is recommended for individuals with known mutations planning to have children.

Complications

Untreated PPGLs can cause life-threatening cardiovascular complications including stroke, heart attack, severe hypertension, and cardiac arrhythmias. The extreme blood pressure fluctuations may lead to organ damage affecting the kidneys, eyes, and brain. Catecholamine crisis can occur spontaneously or be triggered by surgery, anesthesia, or certain medications, potentially causing cardiovascular collapse. Malignant PPGLs may metastasize to bones, liver, lungs, or lymph nodes. Pregnancy in women with undiagnosed PPGL carries extremely high maternal and fetal mortality risk due to catecholamine surges during labor.

Diagnosis

Diagnosis begins with biochemical testing measuring catecholamines and their metabolites in 24-hour urine collections or blood samples. Key tests include plasma metanephrines, urinary catecholamines, and urinary vanillylmandelic acid (VMA). Elevated levels typically exceed two to three times the upper normal limit.

Imaging studies locate tumors using CT or MRI scans of the abdomen and pelvis, and sometimes chest or head and neck regions. Functional imaging with MIBG (iobenguane) scintigraphy, which shows iobenguane-avid tumors, or specialized PET scans help identify tumor location and detect metastases. Genetic testing is recommended for all patients to identify hereditary syndromes and guide family screening. Tissue biopsy is generally avoided due to risk of triggering catecholamine crisis.

Treatment

Surgical removal is the primary treatment for localized PPGLs. Preoperative medical management with alpha-blockers like phenoxybenzamine is essential to control blood pressure and prevent catecholamine crisis during surgery. Beta-blockers may be added after adequate alpha-blockade to control heart rate.

For metastatic disease, iobenguane I-131 provides targeted radiotherapy for tumors that concentrate this radioactive compound. Chemotherapy combinations like cyclophosphamide, vincristine, and dacarbazine may be used for aggressive metastatic cases. External beam radiation therapy can provide palliative treatment for bone metastases. Clinical trials are investigating novel targeted therapies and immunotherapies for advanced disease.

Prognosis

The prognosis is excellent for benign PPGLs when diagnosed and treated appropriately, with five-year survival rates exceeding 95%. Complete surgical removal typically cures benign tumors, though lifelong follow-up is necessary to monitor for recurrence, especially in hereditary cases. Malignant PPGLs have more variable outcomes, with five-year survival rates of 50-80% depending on the extent of metastatic disease and response to treatment. Early detection through family screening in hereditary syndromes significantly improves outcomes by allowing treatment before complications develop.

Quality of life

Successful treatment dramatically improves quality of life by eliminating debilitating symptoms and reducing cardiovascular risk. Patients can typically return to normal activities within weeks to months after surgery. Regular exercise is encouraged once cleared by physicians, as it helps maintain cardiovascular health. Stress management techniques may help reduce symptom triggers in those with residual disease.

Dietary modifications include limiting caffeine and alcohol, which can trigger symptoms in susceptible individuals. Sleep quality often improves significantly after treatment as night sweats and anxiety resolve. Mental health support may be beneficial, as living with a rare disease and facing potential hereditary implications can cause anxiety. Patients with hereditary syndromes may need ongoing surveillance appointments, but this allows for early intervention if new tumors develop.

Pregnancy and fertility

PPGL poses significant risks during pregnancy due to catecholamine surges that can occur during labor and delivery. Women with known or suspected PPGL should undergo evaluation before conception when possible. If diagnosed during pregnancy, careful multidisciplinary management involving endocrinologists, high-risk obstetricians, and anesthesiologists is essential. Alpha-blockers like phenoxybenzamine are generally considered safe during pregnancy. Surgical removal may be performed during the second trimester if necessary. Genetic counseling is crucial for individuals with hereditary forms planning pregnancy, as some syndromes carry a 50% risk of transmission to offspring.

Children

Pediatric PPGL is more likely to be hereditary, with up to 80% of cases associated with genetic syndromes. Children may present with similar symptoms to adults, though sustained hypertension is more common than episodic symptoms. Growth delays and behavioral changes may be additional presenting features. Genetic testing is particularly important in pediatric cases to identify the underlying syndrome and initiate appropriate surveillance. Treatment approaches are similar to adults, though surgical techniques and medication dosing require pediatric expertise. Long-term follow-up is essential given the higher likelihood of hereditary disease and potential for developing additional tumors throughout life.

When to see a doctor

Seek immediate medical attention for: severe headache with profuse sweating and rapid heartbeat, blood pressure readings consistently above 180/110 mmHg, chest pain with palpitations, or symptoms suggesting stroke such as sudden weakness, speech difficulties, or vision changes.

Schedule routine evaluation for: recurrent episodes of headaches, sweating, and palpitations occurring together, unexplained hypertension especially in young people, family history of PPGL or related genetic syndromes, or incidental discovery of adrenal masses on imaging studies. Early diagnosis prevents potentially life-threatening complications and allows for optimal treatment outcomes.

Regional context

Specific prevalence data for PPGL in the Caucasus region (Georgia, Armenia, Azerbaijan) and Eastern Mediterranean countries is limited. The global incidence appears consistent across populations, though certain genetic variants may be more common in specific ethnic groups. Regional medical centers are increasingly developing expertise in managing rare endocrine tumors, and international collaboration helps ensure access to specialized diagnostic testing and treatment options. The Global Medical Journal welcomes contributions from healthcare providers in these regions to better understand local disease patterns and improve patient care.

Research and clinical trials

Current research focuses on developing novel targeted therapies for metastatic PPGL, including drugs targeting angiogenesis pathways, mTOR inhibitors, and immunotherapy approaches. Studies are investigating the role of genetic testing in guiding surveillance protocols and treatment decisions. Researchers are exploring new radiopharmaceuticals for both imaging and therapy of neuroendocrine tumors.

Recent breakthroughs include improved understanding of the genetic basis of hereditary syndromes and development of functional imaging techniques that better characterize tumor biology. Clinical trials are evaluating combination therapies and personalized treatment approaches based on tumor genetics. Patients can search for relevant trials at ClinicalTrials.gov using terms like “pheochromocytoma,” “paraganglioma,” or “neuroendocrine tumor.”

Frequently asked questions

Can PPGL be cured?

Yes, benign PPGLs can typically be cured with complete surgical removal. Even malignant forms may be controlled for years with appropriate treatment, and some patients achieve long-term remission.

Will my children inherit this condition?

If you have a hereditary form (about 40% of cases), each child has a 50% chance of inheriting the genetic mutation. However, not everyone with a mutation will develop tumors, and genetic counseling can help assess individual risks.

How often do I need follow-up after treatment?

Follow-up schedules depend on whether you have hereditary or sporadic disease. Most patients need annual biochemical testing and periodic imaging, while those with hereditary syndromes may require more frequent surveillance.

Are there dietary restrictions I should follow?

Most patients can follow a normal diet after successful treatment. Some may need to limit caffeine or alcohol if these trigger symptoms. Your healthcare team can provide specific guidance based on your situation.

Can stress trigger PPGL symptoms?

Yes, physical or emotional stress can trigger catecholamine release and worsen symptoms in people with active tumors. Stress management techniques and treating the underlying tumor are both important for symptom control.

Support and resources

Patient Organizations:

• Pheo Para Alliance – Primary patient advocacy organization providing support, education, and research funding
• National Organization for Rare Disorders (NORD) – Comprehensive rare disease information and support
• Orphanet – European database of rare diseases and support resources
• EURORDIS – European umbrella organization for rare disease patient groups
• World Health Organization Rare Diseases – Global health policy and information

Related conditions

Multiple Endocrine Neoplasia, Von Hippel-Lindau Disease, Neurofibromatosis Type 1, Carcinoid Syndrome, Adrenal Insufficiency

Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, relevant guidelines. Informational only; not medical advice. CC BY 4.0.

Licensed under CC BY 4.0. Free to share with attribution to GMJ News.

Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, EULAR/ACR guidelines. Schema.org MedicalCondition structured data included.